JERAYGO
As listed in the register: JERAYGO
12.5 mg · tablet
- Prescription only
- Heart, blood pressure and circulation
- Active substance
- Aprocitentan
- Made by
- Idorsia Pharmaceuticals Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (TRYVIO). It describes the substance, not this exact product.
Aprocitentan is an ERA that inhibits the binding of endothelin (ET)-1 to ET A and ET B receptors.
ET-1, via its receptors (ET A and ET B ), mediates a variety of deleterious effects such as vasoconstriction, fibrosis, cell proliferation, and inflammation.
Aprocitentan is primarily metabolized by UGT1A1- and UGT2B7-mediated N-glucosidation and non-enzymatic hydrolysis.
After a single dose of radiolabeled aprocitentan, approximately 52% of the dose was eliminated via urine (0.2% unchanged) and 25% via feces (6.8% unchanged).
Effect of Food No clinically significant differences in aprocitentan pharmacokinetics were observed following administration of a high-fat, high-calorie meal (approximately 150, 250, and 500–600 calories from protein, carbohydrate, and fat, respectively) in healthy subjects.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-14
Safety of the active substance
From the US prescribing label for the same active substance (TRYVIO). It describes the substance, not this exact product.
WARNING: EMBRYO-FETAL TOXICITY TRYVIO is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients.
- Pregnancy ( 4.1 ) Hypersensitivity ( 4.2 ) 4.1 Pregnancy Use of TRYVIO is contraindicated in patients who are pregnant [see Dosage and Administration (2.2), Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. 4.2 Hypersensitivity TRYVIO is contraindicated in patients who are hypersensitive to aprocitentan or any of its excipients [see Adverse Reactions (6.1) ].
The most frequently reported adverse reactions to TRYVIO during the 4-week double-blind placebo-controlled treatment period (part 1) of the PRECISION study are presented in Table 1.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Idorsia Pharmaceuticals Ltd |
|---|---|
| Active substance | Aprocitentan |
| Used in | Heart, blood pressure and circulation |
| Strength | 12.5 mg |
| Form | tablet |
| Classification | C02KN01 · Heart, blood pressure and circulation |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02563983 |
| DPD drug code | 106672 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- tablet2 products
- 12.5 mg
- 25 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.